Efficacy and Safety Study of PEG-rIL-29 Plus Ribavirin to Treat Chronic Hepatitis C Virus Infection (EMERGE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01001754
Recruitment Status : Unknown
Verified December 2011 by ZymoGenetics.
Recruitment status was:  Active, not recruiting
First Posted : October 27, 2009
Last Update Posted : December 5, 2011
Bristol-Myers Squibb
Information provided by (Responsible Party):